MDXG
$4.36
MiMedx Group, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PU...
Recent News
How The MiMedx Group (MDXG) Investment Story Is Shifting On Reimbursement Risk And Recovery Hopes
The updated analyst fair value estimate for MiMedx Group has shifted only slightly, from US$9.60 to about US$9.67 per share, but that small move sits against a backdrop of more active price target changes across recent research. Some analysts link their revised targets in the US$8 to US$10 range to ongoing questions about Medicare reimbursement and how that could affect execution and cash flow. As you read on, you will see how these changing price targets fit into the broader analyst...
MiMedx Group (MDXG) Delivers Record Full Year Revenue
MiMedx Group, Inc. (NASDAQ:MDXG) is one of the Best 52-Week Low Penny Stocks to Invest In. On February 25, MiMedx Group, Inc. (NASDAQ:MDXG) delivered record quarterly and full-year revenue and profitability. This was driven by the company’s wound care and surgical segments, both delivering double-digit growth. The company grew its Q4 revenue by 27.11% year-over-year […]
MiMedx Group Q4 Earnings Call Highlights
MiMedx Group (NASDAQ:MDXG) reported fourth-quarter and full-year 2025 results that management said topped internal expectations, supported by strong growth in both its wound care and surgical segments. On the company’s earnings call, executives also focused heavily on disruption in the wound care ma
MiMedx Group Inc (MDXG) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...
MiMedx Group Inc (MDXG) reports a robust 27% increase in net sales and unveils a $100 million share repurchase program amidst market challenges.
MiMedx (MDXG) Q4 Earnings and Revenues Beat Estimates
MiMedx (MDXG) delivered earnings and revenue surprises of +55.56% and +14.93%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?